

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 October 2022 (27.10.2022)



(10) International Publication Number  
**WO 2022/226388 A1**

(51) International Patent Classification:

A61K 31/4245 (2006.01) A61K 31/437 (2006.01)  
A61K 31/427 (2006.01) A61K 31/44 (2006.01)  
A61P 9/04 (2006.01) A61K 31/505 (2006.01)  
A61K 31/165 (2006.01) A61K 31/506 (2006.01)  
A61K 31/422 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2022/026065

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,901 23 April 2021 (23.04.2021) US

(71) Applicant: **TENAYA THERAPEUTICS, INC.** [US/US];  
171 Oyster Point Boulevard, Suite 500, South San Francisco,  
California 94080 (US).

(72) Inventors: **MANDEGAR, Mohammad A.**; c/o Tenaya  
Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 500,  
South San Francisco, California 94080 (US). **YANG, Jin**;  
c/o Tenaya Therapeutics, Inc., 171 Oyster Point Boulevard,  
Suite 500, South San Francisco, California 94080 (US).

**HOEY, Timothy C.**; c/o Tenaya Therapeutics, Inc., 171  
Oyster Point Boulevard, Suite 500, South San Francisco,  
California 94080 (US).

(74) Agent: **ELBERT, Maya** et al.; COOLEY LLP, 1299 Penn-  
sylvania Avenue NW, Suite 700, Washington, District of  
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: HDAC6 INHIBITORS FOR USE IN THE TREATMENT OF DILATED CARDIOMYOPATHY

(57) Abstract: Provided are methods of treating or preventing dilated cardiomyopathy (DCM) with an HDAC6 inhibitor. A variety of HDAC6 inhibitors are described for use in treating or preventing DCM. In one aspect, described herein are methods of treating a human patient by orally administering an HDAC6 inhibitor, such as an inhibitor of Formula (I) or Formula (II). In one aspect, described herein are methods of treating a human patient with DCM associated with a reduced ejection fraction.




FIG. 1

WO 2022/226388 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*